Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Sarcoma, Kaposi | 2 | 2020 | 97 | 0.82 | Why? |
| Tuberculoma | 1 | 2018 | 6 | 0.77 | Why? |
| Tuberculosis, Cutaneous | 1 | 2018 | 14 | 0.76 | Why? |
| Chylothorax | 1 | 2017 | 5 | 0.73 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 1 | 2018 | 66 | 0.72 | Why? |
| Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 81 | 0.70 | Why? |
| Meningitis, Cryptococcal | 1 | 2018 | 79 | 0.70 | Why? |
| Tularemia | 1 | 2017 | 25 | 0.68 | Why? |
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2018 | 82 | 0.66 | Why? |
| Gastrectomy | 1 | 2017 | 225 | 0.61 | Why? |
| HIV Infections | 6 | 2020 | 11620 | 0.52 | Why? |
| Adalimumab | 1 | 2017 | 389 | 0.50 | Why? |
| Anti-Retroviral Agents | 2 | 2018 | 1099 | 0.49 | Why? |
| Hepatitis E | 1 | 2017 | 319 | 0.49 | Why? |
| Ageusia | 1 | 2020 | 918 | 0.48 | Why? |
| Sofosbuvir | 1 | 2017 | 518 | 0.47 | Why? |
| Heart Transplantation | 3 | 2020 | 1293 | 0.46 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2017 | 533 | 0.43 | Why? |
| Arthritis, Psoriatic | 1 | 2017 | 625 | 0.43 | Why? |
| Ribavirin | 1 | 2017 | 1182 | 0.40 | Why? |
| Hepatitis B | 1 | 2017 | 888 | 0.37 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2017 | 2483 | 0.32 | Why? |
| Autoantibodies | 1 | 2018 | 2094 | 0.32 | Why? |
| Obesity, Morbid | 1 | 2017 | 1340 | 0.32 | Why? |
| HIV-1 | 2 | 2018 | 3365 | 0.31 | Why? |
| Laparoscopy | 1 | 2017 | 1532 | 0.30 | Why? |
| Neuromyelitis Optica | 2 | 2021 | 397 | 0.30 | Why? |
| Hydroxychloroquine | 4 | 2021 | 12447 | 0.30 | Why? |
| Occupational Diseases | 1 | 2020 | 2787 | 0.29 | Why? |
| Paris | 4 | 2021 | 1287 | 0.28 | Why? |
| Coinfection | 4 | 2020 | 6820 | 0.24 | Why? |
| Antirheumatic Agents | 1 | 2017 | 3023 | 0.23 | Why? |
| Transplant Recipients | 1 | 2018 | 4982 | 0.23 | Why? |
| France | 6 | 2021 | 12074 | 0.22 | Why? |
| Antigens, CD20 | 1 | 2020 | 105 | 0.21 | Why? |
| Lung Neoplasms | 1 | 2017 | 3228 | 0.21 | Why? |
| Compassionate Use Trials | 2 | 2021 | 632 | 0.20 | Why? |
| Moldova | 1 | 2018 | 5 | 0.20 | Why? |
| Herpesvirus 8, Human | 1 | 2020 | 97 | 0.19 | Why? |
| Quasispecies | 1 | 2020 | 108 | 0.19 | Why? |
| Immunosuppressive Agents | 5 | 2021 | 6331 | 0.19 | Why? |
| Multiple Sclerosis, Chronic Progressive | 1 | 2020 | 136 | 0.18 | Why? |
| Brain Diseases | 2 | 2020 | 1463 | 0.18 | Why? |
| Interferon beta-1a | 1 | 2021 | 316 | 0.18 | Why? |
| Cellular Microenvironment | 1 | 2017 | 55 | 0.17 | Why? |
| Francisella tularensis | 1 | 2017 | 28 | 0.17 | Why? |
| Tuberculosis, Miliary | 1 | 2018 | 66 | 0.17 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.17 | Why? |
| Potentially Inappropriate Medication List | 1 | 2017 | 55 | 0.17 | Why? |
| Hepatitis, Chronic | 1 | 2017 | 53 | 0.17 | Why? |
| Certolizumab Pegol | 1 | 2017 | 36 | 0.17 | Why? |
| Gentamicins | 1 | 2017 | 76 | 0.17 | Why? |
| Medication Errors | 1 | 2017 | 107 | 0.16 | Why? |
| Memory Disorders | 1 | 2018 | 190 | 0.16 | Why? |
| Ciprofloxacin | 1 | 2017 | 130 | 0.15 | Why? |
| Abscess | 1 | 2018 | 234 | 0.15 | Why? |
| Farms | 1 | 2017 | 269 | 0.15 | Why? |
| Lymphoma | 1 | 2021 | 522 | 0.15 | Why? |
| Outpatient Clinics, Hospital | 1 | 2020 | 523 | 0.15 | Why? |
| Multiple Sclerosis | 2 | 2021 | 2600 | 0.14 | Why? |
| Liver Transplantation | 2 | 2020 | 2864 | 0.14 | Why? |
| Doxycycline | 1 | 2017 | 307 | 0.14 | Why? |
| Inappropriate Prescribing | 1 | 2017 | 284 | 0.13 | Why? |
| Sarcoidosis | 1 | 2017 | 271 | 0.13 | Why? |
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2020 | 529 | 0.13 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.13 | Why? |
| Hepatitis E virus | 1 | 2017 | 306 | 0.13 | Why? |
| Rabbits | 1 | 2017 | 1171 | 0.13 | Why? |
| General Practitioners | 1 | 2020 | 568 | 0.13 | Why? |
| Methotrexate | 1 | 2017 | 471 | 0.12 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2017 | 724 | 0.12 | Why? |
| Antiviral Agents | 5 | 2021 | 41703 | 0.12 | Why? |
| Adipose Tissue | 1 | 2017 | 612 | 0.12 | Why? |
| Antitubercular Agents | 1 | 2018 | 775 | 0.11 | Why? |
| Orthomyxoviridae | 1 | 2020 | 1168 | 0.11 | Why? |
| Weight Loss | 1 | 2017 | 826 | 0.11 | Why? |
| Checklist | 1 | 2017 | 714 | 0.11 | Why? |
| Internal Medicine | 1 | 2017 | 557 | 0.11 | Why? |
| Cytomegalovirus Infections | 1 | 2018 | 667 | 0.11 | Why? |
| Opportunistic Infections | 1 | 2017 | 602 | 0.11 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.11 | Why? |
| Alanine Transaminase | 1 | 2017 | 1329 | 0.11 | Why? |
| Tissue Donors | 1 | 2020 | 1679 | 0.10 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2017 | 830 | 0.10 | Why? |
| Humans | 32 | 2021 | 930598 | 0.10 | Why? |
| Cats | 1 | 2017 | 1890 | 0.10 | Why? |
| Graft Rejection | 1 | 2020 | 1766 | 0.10 | Why? |
| Immunocompromised Host | 4 | 2020 | 5150 | 0.10 | Why? |
| Male | 18 | 2021 | 367725 | 0.10 | Why? |
| Lopinavir | 2 | 2021 | 4308 | 0.10 | Why? |
| Rituximab | 1 | 2017 | 1096 | 0.10 | Why? |
| Dogs | 1 | 2017 | 2529 | 0.10 | Why? |
| Mycobacterium tuberculosis | 1 | 2018 | 1164 | 0.09 | Why? |
| Ritonavir | 2 | 2021 | 4212 | 0.09 | Why? |
| Hospitals, University | 1 | 2021 | 4173 | 0.09 | Why? |
| Respiratory System | 1 | 2020 | 3213 | 0.09 | Why? |
| Recovery of Function | 1 | 2018 | 2461 | 0.09 | Why? |
| Female | 17 | 2021 | 380317 | 0.09 | Why? |
| Adult | 12 | 2021 | 244371 | 0.08 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.08 | Why? |
| Immunoglobulins, Intravenous | 1 | 2018 | 2705 | 0.08 | Why? |
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 1692 | 0.08 | Why? |
| Patient Selection | 1 | 2020 | 4560 | 0.07 | Why? |
| Magnetic Resonance Imaging | 2 | 2020 | 6551 | 0.07 | Why? |
| Follow-Up Studies | 3 | 2020 | 17020 | 0.07 | Why? |
| Brain | 2 | 2020 | 5133 | 0.07 | Why? |
| Rural Population | 1 | 2017 | 2408 | 0.07 | Why? |
| Hematologic Neoplasms | 1 | 2017 | 2105 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2017 | 1996 | 0.07 | Why? |
| Electrocardiography | 1 | 2018 | 3957 | 0.07 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.07 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.06 | Why? |
| Ambulatory Care | 1 | 2020 | 4947 | 0.06 | Why? |
| Virus Diseases | 1 | 2020 | 3779 | 0.06 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4545 | 0.06 | Why? |
| Primary Health Care | 1 | 2020 | 4839 | 0.06 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.05 | Why? |
| Viral Load | 2 | 2020 | 15850 | 0.05 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.05 | Why? |
| Epidemics | 1 | 2020 | 6407 | 0.05 | Why? |
| Cerebellar Diseases | 1 | 2020 | 90 | 0.05 | Why? |
| Aged | 6 | 2021 | 215776 | 0.05 | Why? |
| Frontal Lobe | 1 | 2020 | 191 | 0.05 | Why? |
| Natalizumab | 1 | 2020 | 144 | 0.05 | Why? |
| Myoclonus | 1 | 2020 | 133 | 0.05 | Why? |
| Postoperative Complications | 1 | 2018 | 5861 | 0.05 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.05 | Why? |
| Fingolimod Hydrochloride | 1 | 2020 | 217 | 0.05 | Why? |
| Pancreas Transplantation | 1 | 2020 | 163 | 0.05 | Why? |
| Anti-Bacterial Agents | 2 | 2018 | 10083 | 0.04 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.04 | Why? |
| Antibodies, Monoclonal | 1 | 2017 | 8041 | 0.04 | Why? |
| Ganciclovir | 1 | 2018 | 97 | 0.04 | Why? |
| Status Epilepticus | 1 | 2020 | 303 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Prospective Studies | 2 | 2020 | 43301 | 0.04 | Why? |
| Cyclophosphamide | 1 | 2017 | 387 | 0.04 | Why? |
| Practice Guidelines as Topic | 1 | 2020 | 15421 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Radiopharmaceuticals | 1 | 2020 | 763 | 0.04 | Why? |
| Neuropsychological Tests | 1 | 2020 | 954 | 0.04 | Why? |
| Central Nervous System | 1 | 2021 | 701 | 0.04 | Why? |
| Cognition Disorders | 1 | 2020 | 574 | 0.04 | Why? |
| Neutropenia | 1 | 2018 | 388 | 0.03 | Why? |
| Intestines | 1 | 2020 | 817 | 0.03 | Why? |
| Electroencephalography | 1 | 2020 | 1242 | 0.03 | Why? |
| HIV | 1 | 2020 | 1116 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.03 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2020 | 1153 | 0.03 | Why? |
| Neoplasm Recurrence, Local | 1 | 2020 | 1063 | 0.03 | Why? |
| Pseudomonas aeruginosa | 1 | 2018 | 652 | 0.03 | Why? |
| Viremia | 1 | 2020 | 1020 | 0.03 | Why? |
| Delphi Technique | 1 | 2017 | 1257 | 0.03 | Why? |
| Anxiety | 1 | 2018 | 17311 | 0.03 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.03 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.03 | Why? |
| Waiting Lists | 1 | 2020 | 1388 | 0.03 | Why? |
| Drug Combinations | 1 | 2021 | 3852 | 0.03 | Why? |
| Young Adult | 2 | 2020 | 93724 | 0.03 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 1458 | 0.03 | Why? |
| Pneumonia, Bacterial | 1 | 2018 | 843 | 0.03 | Why? |
| Flow Cytometry | 1 | 2017 | 2393 | 0.02 | Why? |
| Lung Transplantation | 1 | 2020 | 1554 | 0.02 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.02 | Why? |
| Disease Reservoirs | 1 | 2017 | 1672 | 0.02 | Why? |
| Shock, Septic | 1 | 2018 | 1313 | 0.02 | Why? |
| Preoperative Care | 1 | 2018 | 1515 | 0.02 | Why? |
| Animals | 1 | 2017 | 78931 | 0.02 | Why? |
| Immunotherapy | 1 | 2020 | 2421 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.01 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.01 | Why? |
| Viral Proteins | 1 | 2020 | 7370 | 0.01 | Why? |
| Phylogeny | 1 | 2020 | 13341 | 0.01 | Why? |
| Adrenal Cortex Hormones | 1 | 2017 | 6537 | 0.01 | Why? |
| Kidney Transplantation | 1 | 2020 | 5397 | 0.01 | Why? |
| Mutation | 1 | 2020 | 12376 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Attitude of Health Personnel | 1 | 2017 | 4741 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2020 | 88759 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.01 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.01 | Why? |
| Registries | 1 | 2017 | 12327 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| Mental Disorders | 1 | 2020 | 6742 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2017 | 11041 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Heart Failure | 1 | 2018 | 6638 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Lung | 1 | 2020 | 31049 | 0.01 | Why? |
| Child | 1 | 2020 | 70012 | 0.01 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.01 | Why? |
| Risk Factors | 1 | 2017 | 71621 | 0.01 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.01 | Why? |
Pourcher's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(201)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(192)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_